The registrational intent ACR-368 Phase 2b study is advancing with a prespecified simultaneous interim analysis and data update for both all-comer (biopsy-independent) serous endometrial cancer arms in second half 2026 The ACR-2316 Phase 1/2 study is advancing towards expansion phase demonstrating favorable tolerability, primarily transient neutropenia, with durable clinical activity at weekly dosing regimens in subjects with AP3- prioritized tumors, including heavily pretreated lung cancers Cash, cash equi ...

ROSEVILLE, Minn., May 13, 2026 (GLOBE NEWSWIRE) -- Hawkins, Inc. (Nasdaq: HWKN) today announced fourth quarter and full-year results for its fiscal year ended March 29, 2026. "Fiscal 2026 was another milestone year for our company, as we crossed $1 billion in revenue, for the first time in our history. My thanks to every person connected to our great company for helping us accomplish this goal. This achievement resulted in a number of records for the year; including sales, gross margin, operating income, an ...

COCONUT CREEK, Fla., May 13, 2026 (GLOBE NEWSWIRE) -- Willis Lease Finance Corporation (NASDAQ: WLFC) (the "Company"), the leading lessor of commercial aircraft engines and global provider of aviation services, announced today its intention to offer, subject to market and other conditions, $175.0 million aggregate principal amount of convertible senior notes due 2031 (the "Notes") in a public offering (the "Notes Offering") registered under the Securities Act of 1933, as amended (the "Act"). The Company int ...

First clinical data from PRMT5/RAS(ON) combination trial to be presented in 2026 Cash position of $380 million as of March 31, 2026, with runway into 2028 beyond anticipated key data inflection points BOSTON, May 13, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical- stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today reported financial results for the first quarter ended March 31, 2026, and provided business ...

COLUMBIA, Mo., May 13, 2026 (GLOBE NEWSWIRE) -- EquipmentShare.com Inc (Nasdaq: EQPT) ("EquipmentShare" or the "Company") today reported financial results for the first quarter ended March 31, 2026 which can be found on EquipmentShare's website at https://ir.equipmentshare.com/. "We delivered a strong first quarter and are raising our 2026 outlook across the board," said Jabbok Schlacks, Founder and Chief Executive Officer of EquipmentShare. "Rental Segment revenue grew 37% year over year, supported by stro ...

LONG BEACH, Calif. and TORONTO, May 13, 2026 (GLOBE NEWSWIRE) -- Glass House Brands Inc. ("Glass House" or the "Company") (CBOE CA: GLAS.A.U) (CBOE CA: GLAS.WT.U) (OTCQX: GLASF) (OTCQX: GHBWF), one of the fastest-growing, vertically integrated cannabis companies in the U.S., today reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 Highlights (Unaudited results, unless otherwise stated, all results and dollar references are in U.S. dollars) Management Commentary "The re ...

Added 7 top-rated children's hospitals to QUELIMMUNE pediatric acute kidney injury (AKI) customer base, increasing first quarter revenue 69% versus first quarter 2025 revenue Advanced enrollment in the NEUTRALIZE-AKI pivotal clinical trial in adult patients with AKI Initiated efforts for the submission of a modular post-marketing application (PMA) Anticipated 2026 Milestones DENVER, May 13, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focu ...

JUPITER, Fla., May 13, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ: DYAI), d/b/a Dyadic Applied BioSolutions, a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for diverse commercial applications, today reported its financial results for Q1 2026 along with significant corporate achievements. "Throughout 2025 and into early 2026, we remained focused on transforming Dyadic into a commercially driven o ...

MIAMI, May 13, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today reported financial results for the quarter ended March 31, 2026 and provided a business update. "Earlier this year, we initiated a strategic repositioning of Longeveron designed to maximize shareholder value while maintaining disciplined capital allocation," said Stephen H. Willard, Chief Ex ...

核心观点 - 公司2026年第一季度营收为420万美元，同比增长32%，主要得益于水处理和空气业务收入的增长，但被一次性许可费收入缺失部分抵消 [1][6] - 公司成功登陆NYSE American交易所并完成1640万美元的融资，显著增强了资产负债表并扩大了投资者基础 [4][7][10] - 公司推出了SEA-IX™核级离子交换树脂产品线，并已获得约100万美元的初始订单，进入了估计规模为2.2亿美元的可寻址市场 [1][4][7] - 公司正在积极追讨美国特拉华州地区法院判给的约7800万美元专利侵权最终判决款项，被告已上诉但未提供保证金，判决后利息持续累积 [1][4][7] - 公司任命了新的首席财务官，并计划参加多个行业会议，以加强团队和业务拓展 [5][7] 2026年第一季度财务业绩 - **营收**：2026年第一季度营收为420万美元，较去年同期的320万美元增长32% [6] - **毛利与毛利率**：毛利为140万美元，高于去年同期的120万美元，毛利率增长主要得益于收入增加，但部分被高利润率许可收入的减少所抵消 [8] - **费用**：销售、一般及行政管理费用为200万美元，低于去年同期的220万美元，主要原因是法律费用降低 [8] - **研发费用**：研发费用为60万美元，高于去年同期的40万美元，主要用于开发采用新型吸附剂技术的水处理产品 [9] - **净亏损**：净亏损为130万美元，或每股基本及摊薄亏损0.06美元，较去年同期的净亏损170万美元（每股0.09美元）有所收窄 [9] - **调整后EBITDA**：调整后EBITDA亏损从2025年第一季度的120万美元改善至2026年第一季度的100万美元 [10][17] - **现金状况**：截至2026年3月31日，现金总额为1470万美元，无债务；相比2025年12月31日的220万美元大幅增加，主要反映了2026年2月完成1640万美元融资的影响 [10] 运营与战略进展 - **资本市场动作**：2026年2月成功转板至NYSE American，并同步完成公开发行，筹集总额约1640万美元 [4][7][10] - **新产品发布**：推出SEA-IX™核级离子交换树脂产品线，目标市场包括核电、燃煤公用事业和市政水处理，估计市场规模达2.2亿美元，目前已获得约100万美元的初始采购订单 [1][4][7] - **业务拓展**：水处理解决方案业务获得现有中大西洋公用事业客户的新供应订单以及新的项目奖项 [4] - **技术合作**：与国家工程公司Civil & Environmental Consultants合作，通过公司在北达科他州大福克斯的分析设计中心，向CEC的全国水公用事业客户群提供RSSCT测试服务 [7] - **管理团队加强**：2026年5月，任命Michael Mioska为首席财务官，接替Fiona Fitzmaurice [5][7] - **市场活动**：宣布将参加并参展2026年5月和6月的四场水行业会议，包括在华盛顿特区举行的AWWAACE26年度会议与博览会 [7] 公司背景 - 公司是特种活性炭技术领域的领导者，专注于为空气和水净化提供创新解决方案，以支持更清洁、更可持续的未来 [13] - 核心业务包括为燃煤公用事业部门提供专利的SEA®吸附剂技术以捕捉汞排放，以及专注于去除饮用水和工业废水中污染物（包括PFAS等“永久化学品”）的颠覆性水净化技术 [13] - 公司拥有强大的知识产权组合和活性炭专家团队 [13]